胆膵領域の病理学研究

主な担当メンバー:田中麻理子、山内直子、安永瑛一

予後不良であり本邦死因の第4位を占める膵癌、ならびに難治癌である胆管癌、肝癌を対象としている。病理形態学的特徴と分子生物学的性質を照らし合わせた発癌過程の解明、形態学的予後不良指標の同定などを進めている。

<参考文献>

  1. EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma. Tanaka M, Shibahara J, Ishikawa S, Ushiku T, Morikawa T, Shinozaki-Ushiku A, Hayashi A, Misumi K, Tanaka A, Katoh H, Sakuma K, Kokudo T, Inagaki Y, Arita J, Sakamoto Y, Hasegawa K, Fukayama M. Virchows Arch. 2019;474(1):39-46.
  2. Pancreatic Lipomatous Hamartoma: A Hitherto Unrecognized Variant. Tanaka M, Ushiku T, Ikemura M, Takazawa Y, Igari T, Shimizu M, Yamaguchi H, Fukushima N, Sakuma K, Arita J, Sakamoto Y, Hasegawa K, Watadani T, Nakai Y, Koike K, Fukayama M. Am J Surg Pathol. 2018;42(7):891-897.
  3. EVI1 modulates oncogenic role of GPC1 in pancreatic carcinogenesis. Tanaka M, Ishikawa S, Ushiku T, Morikawa T, Isagawa T, Yamagishi M, Yamamoto H, Katoh H, Takeshita K, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M. Oncotarget. 2017;8(59):99552-99566.
  4. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S, Fukayama M. Oncogene. 2014;8;33(19):2454-63.
  5. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, Kokudo N, Fukayama M. J Histochem Cytochem. 2011;59(10):942-52.
  6. Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma. Shinozaki A, Shibahara J, Noda N, Tanaka M, Aoki T, Kokudo N, Fukayama M. Virchows Arch. 2011;459(1):73-80.
  7. Intraductal oncocytic papillary neoplasm of the bile duct: clinicopathologic and immunohistochemical characteristics of 6 cases. Tanaka M, Fukushima N, Noda N, Shibahara J, Kokudo N, Fukayama M. Hum Pathol. 2009;40(11):1543-52.